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Extended pelvic exenterationAbstract Background: The incidence of rectal cancer recurrence after surgery is 5–45%. Extended
pelvic resection which entails En-bloc resection of the tumor and adjacent involved organs provides
the only true possible curative option for patients with locally recurrent rectal cancer.
Aim: To evaluate the surgical and oncological outcome of such treatment.
Patients and methods: Between 2006 and 2012 a consecutive series of 40 patients with locally recur-
rent rectal cancer underwent abdominosacral resection (ASR) in 18 patients, total pelvic exentera-
tion with sacral resection in 10 patients and extended pelvic exenteration in 12 patients. Patients
with sacral resection were 28, with the level of sacral division at S2–3 interface in 10 patients, at
S3–4 in 15 patients and S4–5 in 3 patients.
Results: Forty patients, male to female ratio 1.7:1, median age 45 years (range 25–65 years) under-
went extended pelvic resection in the form of pelvic exenteration and abdominosacral resection.
Morbidity, re-admission and mortality rates were 55%, 37.5%, and 5%, respectively. Mortality
occurred in 2 patients due to perineal ﬂap sepsis and massive myocardial infarction. A R0 and
R1 sacral resection were achieved in 62.5% and 37.5%, respectively. The 5-year overall survival rate
was 22.6% and the 4-year recurrence free survival was 31.8%.
Conclusion: Extended pelvic resection as pelvic exenteration and sacral resection for locally recur-
rent rectal cancer are effective procedures with tolerable mortality rate and acceptable outcome.
The associated morbidity remains high and deserves vigilant follow up.
ª 2014 Production and hosting by Elsevier B.V. on behalf of National Cancer Institute, Cairo University.D license.
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Although the introduction of total mesorectal excision (TME)
[1] and preoperative radiotherapy [2–5] has reduced the number
of local recurrences following surgical resection of rectal cancer,
these recurrences still occur in over 10% of cases and remain a
major concern [6]. Consequentially, most patients with newly
diagnosed local recurrences have already had radiotherapy
before the primary operation. Radiotherapeutic options will
therefore be reduced in future cases of recurrence [7].
While distant disease is the determining factor for prognosis
in most of patients with recurrent rectal cancer, local recur-
rence will generally affect their quality of life [8,9]. Without
treatment, these patients with locally recurrent disease have a
median survival of about 8 months [10,11]. This can be
explained that the uncontrolled local progression is disastrous
for the quality of the remaining life; especially in the absence of
life threatening metastases which can mean prolonged suffer-
ing. Any treatment that could lead to a remission or stabiliza-
tion of the relapse might well be worthwhile. This could mean
that local cure and even prolonged survival might be within
reach for some patients [12].
Aim of this study
The aim of this study is to evaluate the surgical and oncolog-
ical outcome of extended pelvic resection such as pelvic exen-
teration and abdominosacral composite resection for
recurrent rectal cancer.
Patients and methods
Between the years 2006 and 2012, 40 consecutive patients, pre-
sented to the outpatient department, with locally recurrent rec-
tal cancer invading the posterior and/or lateral pelvic walls.
Disease resection was done with the intent of cure, so that to
insure wide resection margins, pelvic organs were removed, if
indicated, up to total pelvic exenteration. Similarly, posteri-
orly, sacral resection was performed if needed, with resection
level ranging from S2–3 to S4–5.
Preoperative evaluation
All patients underwent routine full laboratory blood tests
including base line Carcino-Emberyonic Antigen (CEA), digital
rectal examination (DRE), and diagnostic colonoscopic or
direct biopsy under local anesthesia, for pathological conﬁrma-
tion prior to surgery. Additional routine imaging procedures for
local, regional and distant staging were performed including:
Transrectal ultrasonography (TRUS), chest CT, abdominopel-
vic thin-sectionCT, andMRIwith a phased-array coil. PET–CT
was carried out in selected cases with equivocal metastatic
results or to differentiate between extensive local ﬁbrosis and
disease recurrence. Cystoscopywas done for patients with suspi-
cious, clinical or radiological, urinary bladder involvement.
Patients with tumor invading the sacrum proximally to the
sacral promontory, or encasing the iliac vessels, or passing
through the greater sciatic notch, or circumferentially
involving the lateral pelvic wall, or causing bilateral ureteric
obstruction were excluded. Similarly, patients with unresec-table extra-pelvic disease, or those estimated to be poor
surgical candidates, were also eliminated.
Only the cases with tumor recurrences following primary
R0 resection, received pre-operative (neoadjuvant) radiother-
apy, since all the other cases with primary R1 resection already
received prior adjuvant radiotherapy.
Surgical technique [13]
In all cases, the abdominal sacral resection, which requires a
combined approach, was used. The abdominal part consists
of exploration with careful examination to exclude liver metas-
tases, or signs of extrapelvic spread. Dissection begun at the
lower aortoiliac tree and continued along the hypogastric
artery and vein and includes the obturator nodes. These node
groups are sent separately for pathologic diagnosis (usually
permanent section unless large suspicious nodes are encoun-
tered). Extensive nodal involvement in the lower pelvis would
generally preclude continuing with the resection. However, the
ﬁnding of easily dissectible, though enlarged, obturator nodes
would not preclude resection. Ileal conduit is done whenever
involved ureters or bladder, co-existed with resectable pelvic
tumor. The divided rectum (usually using the stapler) would
be left in the pelvis. Pelvic devascularization is accomplished
by dividing after suture ligating the hypogastric artery and
vein. Additional branches are bisected and suture ligated if
they would lie in the plane of planned resection. The middle
sacral artery and veins, if identiﬁable, are also bisected and
ligated. If the ureters are to be preserved, these are dissected
free from the pelvic ﬂoor and ﬁxed anteriorly to the lateral
pelvic wall just below the external iliac artery and vein, which
prevents injury during the resection for the posterior approach.
The abdomen is closed and the patient is repositioned prone.
A posterior sacral incision is made with one limb curving
about the buttock crease and subcutaneous ﬂaps are raised.
The sciatic nerve is located by splitting the gluteus maximus
muscle in the direction of its ﬁbers (between the ischial tuber-
osity and the greater trochanter) and is encircled by a penrose
drain. The gluteus maximus and medius are dissected from the
sacrum and the sacrotuberous and sacrospinous ligaments are
incised at their attachments to the ischial tuberosity and ischial
spine. The muscles surrounding the sciatic nerve (pyriformis,
obturator internus and gemelli) are identiﬁed. By inserting a
ﬁnger underneath the sciatic nerve (medial to it) the surgeon
then breaks through the pyriformis muscle and investing endo-
pelvic fascia to assess the level of resection. A laminectomy is
performed proximal to the planned level of sacral resection in
order to ligate the terminal end of the dural sac (Fig. 1). If it is
possible, the proximal sacral roots are identiﬁed and an effort
is made to preserve them by dissecting them free from the por-
tion to be resected from the sacrum (Fig. 2). After the resection
line is determined on both sides of the sacrum, an osteotome is
used to cut across the sacrum. For higher resections above S3,
the line of resection is taken through the sacroiliac joint.
Removed en bloc are the sacrum, pelvic sidewalls, and the
tumor, along the attached structures; bladder and retained rec-
tum, if indicated. Hemostasis is obtained after initially packing
the wound to obtain temporary control. The defect is irrigated
and then reconstructed. The insertions of the gluteus maximus
on the greater trochanter are incised allowing the gluteus max-
imus on each side to be moved medially and to be approxi-
Figure 2 The proximal sacral roots are identiﬁed and an effort is
made to preserve them by dissecting them free from the portion to
be resected from the sacrum.
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amount of skin removed and are sewn together with suction
catheters in place (Fig. 4). Skin grafting may be needed to
cover donor sites if rotational ﬂaps are used.
Postoperative follow-up
Postoperatively, patients were followed up until the end of
2012. For the ﬁrst 2 years, patients were reviewed every
3 months for clinical examination, and serum CEA level. Abd-
omino-pelvic US and CXR were done every 6 months. CT
chest, abdomino-pelvic MRI, and full colonoscopy were
carried out on annual basis. PET–CT was done to investigate
any suspicious ﬁndings during the regular follow-up protocol.
For the following 3 years, patients were checked every
6 months then annually thereafter.
Statistical methods
Datamanagement and analysis were performed using Statistical
Package for Social Sciences (SPSS) vs. 17.Disease free and over-
all survival times were estimated using the methods of Kaplan
and Meier. Differences between survival curves were assessed
for statistical signiﬁcance with the log-rank test. All p-values
are two-sided. p-Values <0.05 were considered signiﬁcant [14].
Results
In total, 40 patients were operated upon. Among whom, 25
(62.5%) were males while 15 (37.5%) were females, with a
male to female ratio of 1.7:1, with a median age of 45 years
(range 25–65 years), and 21 (52.5%) patients recorded to be
above 50 years of age. Primary tumor stage and management,
time interval before recurrence, and patterns of recurrence’s
pathological conﬁrmation, are detailed in Tables 1 and 2,
respectively.
In total, abdominosacral resection (ASR) was done in 18
(45.0%) patients, extended pelvic exenteration in 12 (30.0%)
patients, and total pelvic exenteration with sacral resection in
10 (25.0%) patients. Full surgical details are explored in
Table 3.
Median operative time was 210.3 min (180–390 min).
Median blood loss was 3800 cc (range 500–6000 cc). MedianFigure 1 After inserting a ﬁnger medial and underneath the sciatic ner
level of sacral resection in order to ligate the terminal end of the durahospital stay was 21 (range 7–52) days. Postoperative compli-
cations are detailed in Table 4.
Patients were followed for a median of 50 months, a range
of 22–60 months. The relation of patients’ age, sex, Duke’s
stage at ﬁrst diagnosis, and primary surgery to 4-years’
disease-free survival (DFS) and 5-years’ overall survival (OS)
is presented in Tables 5 and 6, respectively.
Discussion
The therapeutic value of reoperation in cases with isolated
localized rectal cancer recurrences has been hard to assess
because of the widely known pessimistic view that surgical
treatment of these patients is of no value [15]. However, since
it has a tremendous impact on quality of life [6], due to the
often accompanied intractable pain and serious complications
[7], it is worth treatment by aggressive surgical procedures as
this will determine the quality of the remaining life [16], and
the literature shows that only complete resection of theve (diagram), a laminectomy is performed proximal to the planned
l sac (picture).
Figure 3 The muscle ﬂaps are approximated in the midline after laterally incising the insertion of the greater trochanter on the gluteus
maximus.
Figure 4 Skin ﬂaps are rotated as needed and a skin graft may be
required at the donor site of the rotated ﬂap (upper shaded area on
the right).
Table 1 Primary tumor status.
Primary tumor (n= 40) Patient No. (%)
Duke’s stage of primary cancer
B 27 (67.5)
B2 16 (40.0)
B3 11 (27.5)
C 13 (32.5)
Primary tumor management
Primary surgical resection
APR 24 (60.0)
LAR 16 (40.0)
Radiotherapy
Previous adjuvant RT for primary (R1) 15 (37.5)
Neoadjuvant RT for recurrence (R0) 25 (62.5)
APR: abdomino-perineal resection; LAR: low anterior resection;
RT: radiotherapy.
Table 2 Tumor recurrence interval and methods of its tissue
diagnosis.
Tumor recurrences (n= 40) Patient No. (%)
Free time interval after primary resection
Less than 12 months (1st year) 6 (15.0)
From 13–24 months (2nd year) 14 (35.0)
From 25–36 months (3rd year) 12 (30.0)
From 37–48 months (4th year) 6 (15.0)
From 49–60 months (5th year) 2 (5.0)
Recurrent tumor tissue diagnosis
Biopsy at laparotomy 1 (2.5)
Biopsy per rectum 10 (25.0)
Pre-sacral biopsy 26 (65.0)
True-Cut biopsy 22 (55.0)
FNAC (CT guided) 4 (10.0)
PET–CT* 3 (7.5)
FNAC: ﬁne needle aspiration cytology; CT: computerized tomog-
raphy; PET: positron emission tomography.
* Though PET–CT is not a standard tissue diagnosis method, it
was used for tissue differentiation, in addition to the clinical sur-
gery, to take the decision of surgery. Postoperative ﬁnal pathology
supported the decisions.
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patients [17–26]. Thereby, aggressive attempt has to be made
to obtain a microscopically radical resection [15,20]. Conse-
quently, posterior or total exenteration may be indicated in
case of an anteriorly located recurrence, while an abdominosa-
cral resection may be indicated when dealing with a posteriorly
located recurrence [27–29].
Primary stage
In this study, we found no statistical difference between stage
B and C on presentation, on the 5-year overall survival or dis-
ease-free survival, following local resection of the recurrent
disease. These ﬁndings correlate with other authors’ ﬁndings
[30,31], emphasizing the importance of selection of isolated
local pelvis recurrences for this type of aggressive salvage
procedures.
Table 3 Study surgery details.
Detail Patient No. (%)
Procedure classiﬁcation (n= 40)
Curative intent 35 (87.5)
Palliative intent 5 (12.5)
Completeness of surgical resection
R0 25 (62.5)
R1 15 (37.5)
Extent of resection (n= 40)
Abdomino-sacral resection (ASR) 18 (45.0)
Pelvic-exenteration and sacral resection 10 (25.0)
Extended pelvic-exenteration
(bladder/rectum/perineum/soft tissue)
12 (30.0)
Level of sacral resection 28 (70.0)
S2/3 10 (25.0)
S3/4 15 (37.5)
S4/5 3 (7.5)
Pelvic lymph node dissection (PLND) 10 (25.0)
Pelvic organ(s) resected with recurrent rectal cancer (n= 22)
Total 22/40 (55.0)
Rectum 5 (22.7)
Bladder + prostate 10 (45.5)
Bladder + uterus, tubes and ovaries 5 (22.7)
Uterus, tubes and ovaries 2 (9.1)
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In this study, as in other studies [15,32], there was no effect of
primary surgery, on recurrence or survival, between the APR
and the sphincter preserving techniques as LAR, as long as
it maintained a 2 cm clear surgical margin.Table 4 Complications after resection of pelvic recurrence.
Postoperative complication Patient No. (%)
Morbidity (n= 22) 22/40 (55.0%)
Cardiovascular 4
Myocardial ischemia 1
Hypotension 1
Pneumonia 2
Wound complications 9
Perineal dehiscence 3
Flap sloughing 4
Wound infection 2
Urinary complication 4
Small bowel obstruction 5
Mortality (n= 2) 2/40 (5.0%)
Massive myocardial infarctiona 1
Perineal ﬂap sepsisb 1
Hospital re-admissionc (n= 6) 6/40 (15.0%)
Perineal bleeding 3
Intestinal obstruction 2
Perineal hernia 1
a Massive myocardial infarction lead to immediate postoperative
death.
b Perineal ﬂap sepsis, caused pelvic sepsis, which lead to septice-
mia with resultant death after 20 days.
c All managed conservatively.Extent of surgery for recurrence
In this study, the rate of R0 achievement was 62.5%, com-
pared to that reported by other authors ranging between
51% and 68% [33]. Many surgeries reported that achievement
of clear operative margins (R0) conferred a large and signiﬁ-
cant beneﬁt for disease-free survival compared with R1 and
R2 resections (median 45 months vs. 19 and 8 months, respec-
tively, which makes the R1 and R2 surgery practically useless
[31,34]. Thereby, the resection in this type of surgery is usually
extended, since a clear microscopic margin is mandatory,
accordingly we reported other organs’ resection in 55% of
cases. A posterior or total exenteration may be indicated in
case of an anteriorly located recurrence; while an abdominosa-
cral resection may be indicated when dealing with a posteriorly
located recurrence [7].
The bladder is usually the most involved organ, though
many of these involvements could have been simply prevented
during the primary surgery by positioning the ureters up at the
lateral pelvic ﬂoors, instead of leaving them hanging down
[31]. In cases of bladder involvement, especially in those heav-
ily irradiated patients, it is always better to go for planned cys-
tectomy from the beginning, rather than trying partial
cystectomy, with its subsequent frequent urinary ﬁstulae, a
note that has been also advised by other authors [31].
In this series, all cases of abdomino-sacral resection were
performed below the level of S2, which is technically feasible
and can be performed safely [27,28].
Postoperative complications
In this study we report a median operative duration of 3.5 h
compared to 6–14 h reported by other authors [7,13,31], with
a comparative median blood loss 3800 cc vs. 2500–11,500 cc
in the literature [7,24,31,35]. We also report postoperative
complications comparative to other authors, like wound infec-
tion (8.1% vs. 10.0%), wound dehiscence (13.6% vs. 7.5%),
urinary complications (18.2% vs. 20.0%) [7]. Our overall com-
plication rate of 55% was compared to that of 82% reported
by other authors [34]. This marked lower complication rate
might be related to the fact that some series included a much
higher percentage of sacral resection then ours; moreover all
our resections were at lower level than S2, with subsequent
lower complications.
In this study we could not comment on the difference in the
post-operative complication rate between the low (6S3) and
high (PS2–3 disk) level of sacrectomy, since all cases were
resected below S2 level, though some recent studies are report-
ing no signiﬁcant difference between both [34].
The postoperative mortality rate was 5% in our study coin-
ciding with 0–10.7% reported in other publications [31,33,35].
Patients’ survival
In this study, a 5-years’ overall survival of 22.6% was found
compared to 11–51% reported in other studies [7,13,31,33].
This represents a valuable addition when compared to the
4% 5-year survival of palliated patients [13]. Moreover, a 4-
year recurrence free survival of 31.8% was obtained compared
to 20–26% in other studies [7,34,35], which can be explained
by the 1 year difference in the follow-up period. These small
Table 5 Primary tumor stage and surgery type relation’s to 4-years’ local recurrence free.
Primary tumor management Total patients No. Patients with Recurrences No. 4-Years Rec. FS% Median p-Value
Total 40 27 31.8 40
Age groups
650 years 19 12 41.4 39 0.622
>50 years 21 15 37.0 42
Sex
Female 15 10 38.9 39 0.966
Male 25 17 38.8 42
Duke’s stage*
B 27 16 46.9 48 0.081
C 13 11 23.1 37
Primary surgery
APR 24 17 30.7 40 0.934
LAR 16 10 46.1 38
* At primary diagnosis. Rec. FS: recurrence free survival; APR: abdomino-perineal resection; LAR: low anterior resection; RT: radiotherapy.
Table 6 Primary tumor stage and surgery type relation’s to 5-years’ survival.
Primary tumor management Total patients No. Patients with recurrences No. 5-Yrs OS% Median p-Value
Total 40 27 22.6 54
Age groups
650 years 19 12 30.2 50 0.497
>50 years 21 15 13.7 54
Sex
Female 15 10 19.4 50 0.906
Male 25 17 24.4 54
Duke’s stage*
B 27 16 30.8 54 0.368
C 13 11 8.8 54
Primary surgery
APR 24 17 18.2 55 0.977
LAR 16 10 36.7 50
* At primary diagnosis. Yrs: Years; OS: overall survival; APR: abdomino-perineal resection; LAR: low.
172 W. Gawad et al.differences between the overall survival and the disease free
survival, undermine the value of such aggressive procedures
in the amelioration of the quality of life. Overall survival
and disease free survival were not inﬂuenced by the age, sex
of the patients, which is coinciding with other studies [7]. Most
authors demonstrated that R0 resection is the most important
predictor for survival on 5-year survival [33,34,36,37].
Conclusion
Extended pelvic resection as pelvic exenteration and sacral resec-
tion for locally recurrent rectal cancer are effective procedures
with tolerable mortality rate and acceptable outcome. The asso-
ciated morbidity remains high and deserves vigilant follow up.
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